

Company Number: 694076

Aronia Health Science Limited
Abridged Unaudited Financial Statements
for the financial year ended 30 June 2025

Aronia Health Science Limited

CONTENTS

	Page
Directors' Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 10

Aronia Health Science Limited

DIRECTORS' RESPONSIBILITIES STATEMENT

for the financial year ended 30 June 2025

The directors are responsible for preparing the Directors' Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under that law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Directors' Report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Signed on behalf of the board



Steve Collins
Director

6 February 2026



Paul Murphy
Director

6 February 2026

Aronia Health Science Limited

BALANCE SHEET

as at 30 June 2025

	Notes	2025 €	2024 €
Current Assets			
Stocks	7	49,007	22,763
Debtors	8	12,491	7,655
Cash and cash equivalents		25,790	25,896
		<u>87,288</u>	<u>56,314</u>
Creditors: amounts falling due within one year	9	<u>(13,060)</u>	<u>(11,233)</u>
Net Current Assets		<u>74,228</u>	<u>45,081</u>
Total Assets less Current Liabilities		<u>74,228</u>	<u>45,081</u>
Creditors:			
amounts falling due after more than one year	10	<u>(30,000)</u>	<u>(30,000)</u>
Net Assets		<u>44,228</u>	<u>15,081</u>
Capital and Reserves			
Called up share capital presented as equity		130	130
Share premium account	11	199,974	99,974
Retained earnings		(155,876)	(85,023)
Equity attributable to owners of the company		<u>44,228</u>	<u>15,081</u>

We as Directors of Aronia Health Science Limited, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 6 February 2026 and signed on its behalf by:



Steve Collins
Director



Paul Murphy
Director

Aronia Health Science Limited
STATEMENT OF CHANGES IN EQUITY

as at 30 June 2025

	Called up share capital €	Share premium account €	Retained earnings €	Total €
At 1 July 2023	130	99,974	(48,116)	51,988
Loss for the financial year	-	-	(36,907)	(36,907)
At 30 June 2024	130	99,974	(85,023)	15,081
Loss for the financial year	-	-	(70,853)	(70,853)
Net proceeds of equity Ordinary share issue	-	100,000	-	100,000
At 30 June 2025	130	199,974	(155,876)	44,228

Aronia Health Science Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

1. General Information

Aronia Health Science Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 694076. The registered office of the company is Cuibin, Derry Duff, Bantry, Cork which is also the principal place of business of the company. The company develops and markets health supplements derived from Aronia berries which are extremely high in polyphenols and as such, beneficial for metabolic health, endurance and vitality. Initial activity has centred on research and development while simultaneously test marketing prototype products and formats. The current range includes juices, powders and capsules. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 30 June 2025 have been prepared on the going concern basis and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" (FRS 102).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014.

Cash flow statement

The company has availed of the exemption in FRS 102 from the requirement to prepare a Statement of Cash Flows because it is classified as a small company.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Borrowing costs

Borrowing costs relating to the acquisition of assets are capitalised at the appropriate rate by adding them to the cost of assets being acquired. Investment income earned on the temporary investment of specific borrowings pending their expenditure on the assets is deducted from the borrowing costs eligible for capitalisation. All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Aronia Health Science Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

Employee benefits

All employees have access to a PRSA scheme.

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Government grants

Capital grants received and receivable are treated as deferred income and amortised to the Profit and Loss Account annually over the useful economic life of the asset to which it relates. Revenue grants are credited to the Profit and Loss Account when received.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Going concern

The directors have agreed to continue to financially support the company, and will not require their loans to be paid within the next 12 months. All loans are interest free and unsecured.

4. Operating loss

	2025	2024
	€	€
Operating loss is stated after crediting:		
Government grants received	-	(15,000)
	<u> </u>	<u> </u>

5. Employees

The average monthly number of employees, including directors, during the financial year was 2, (2024 - 2).

	2025	2024
	Number	Number
Directors	2	2
	<u> </u>	<u> </u>
	<u> </u>	<u> </u>

Aronia Health Science Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

6. Tax on loss

	2025 €	2024 €
(a) Analysis of charge in the financial year		
Current tax:		
Corporation tax at 12.50% (2024 - 12.50%) (Note 6 (b))	-	-

(b) Factors affecting tax charge for the financial year

The tax assessed for the financial year differs from the standard rate of corporation tax in the Republic of Ireland 12.50% (2024 - 12.50%). The differences are explained below:

	2025 €	2024 €
Loss taxable at 12.50%	<u>(70,853)</u>	<u>(36,907)</u>
Loss before tax multiplied by the standard rate of corporation tax in the Republic of Ireland at 12.50% (2024 - 12.50%)	<u>(8,857)</u>	<u>(4,613)</u>
Effects of:		
Utilisation of tax losses	<u>8,857</u>	<u>4,613</u>
Total tax charge for the financial year (Note 6 (a))	<u>-</u>	<u>-</u>

No charge to tax arises due to tax losses incurred.

7. Stocks

	2025 €	2024 €
Raw materials	-	2,750
Finished goods and goods for resale	<u>49,007</u>	<u>20,013</u>
	<u>49,007</u>	<u>22,763</u>

The replacement cost of stock did not differ significantly from the figures shown.

8. Debtors

	2025 €	2024 €
Trade debtors	12,141	6,040
Taxation	-	1,265
Prepayments	<u>350</u>	<u>350</u>
	<u>12,491</u>	<u>7,655</u>

9. Creditors Amounts falling due within one year

	2025 €	2024 €
Taxation	1,809	-
Directors' current accounts (Note 13)	9,501	9,483
Accruals	<u>1,750</u>	<u>1,750</u>
	<u>13,060</u>	<u>11,233</u>

Aronia Health Science Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

10. Creditors		2025	2024
Amounts falling due after more than one year		€	€
Amounts owed to related parties (Note 14)		10,000	10,000
Directors' loan accounts (Note 13)		20,000	20,000
		30,000	30,000

11. Reserves			
	Share premium account	Profit and loss account	Total
	€	€	€
At 1 July 2024	99,974	(85,023)	14,951
Premium on issue of shares	100,000	-	100,000
Loss for the financial year	-	(70,853)	(70,853)
At 30 June 2025	199,974	(155,876)	44,098

Share Premium Reserve

The amount carried forward is the premium that arose from the issue of shares in 2022. In the year ended 30 June 2025, one of the shareholders provided the company with a further injection of cash. There was no new issue of shares.

12. Capital commitments

The company had no material capital commitments at the financial year-ended 30 June 2025.

13. Directors' remuneration and transactions		2025	2024
		€	€
Fees		-	20,000

The following amounts are repayable to the directors:

		2025	2024
		€	€
Steve Collins		16,280	16,162
Paul Murphy		13,221	13,321
		29,501	29,483

Since inception of the company until period end, the two directors, Paul Murphy and Steve Collins, have spent a number of hours working for no reimbursement. In the event of the success of the company, financial compensation for this time will be paid, we have not accrued for same.

€10,000 and €10,000 was received from Paul Murphy and Steve Collins respectively in relation to loans injected to provide working capital. The balance on the loan accounts relates to miscellaneous expenses and travel and subsistence owed to directors.

Aronia Health Science Limited

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 30 June 2025

14. Related party transactions

	2025 €	2024 €
Amounts falling due after more than one year	<u>10,000</u>	<u>10,000</u>

During the financial period raw materials were purchased from a connected party, namely director Steve Collins t/a Derryduff, in the amount of €1,100 (2024: €3,060). These transactions took place in the ordinary course of business, and there were no amounts owing at the period end.

During the year ended 30 June 2024 a payment of €10,000 in respect of director fee's was accrued in respect of monies owed to Paul Murphy. This amount will be paid when the company has the resources and the funds to do so.

During the year under review, Derry Duff Farm Stays Limited a company wholly owned and controlled by Claire Collins, wife of Steve Collins, Director, provided website and bookkeeping services to the company in the amount of €17,025 (2024: €Nil). The company also sold goods valued at €232 (2024: €394) to Derry Duff Farm Stays Limited. These transactions took place in the ordinary course of business, and there were no amounts owing at the period end.

15. Post-Balance Sheet Events

In January 2026, one of the shareholders, CBA Ventures provided additional funding to the company. No new shares were issued to the shareholder.

16. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 6 February 2026.